Medincell and AbbVie announce a collaboration deal worth up to nearly $2 billion; Inside Headspace and LinkedIn’s interactive content series on work stress; The FDA is working with AbbVie to crack down on fake Botox injections.
Five things for pharma marketers to know for Tuesday morning
More than 250 websites selling fake versions of GLP-1 drugs; FDA places clinical hold on Neumora’s schizophrenia drug; Flonase, Shondaland partner on Bridgerton ads.
Five things for pharma marketers to know for Monday morning
Roche terminates collaboration with Adaptimmune Therapeutics; Siduma Therapeutics closes; CDC report finds COVID-19 vaccines don’t cause fatal cardiac arrest or other deadly heart problems in teens and young adults.
Five things for pharma marketers to know for Friday morning
Eli Lilly’s Mounjaro has limited availability through February; Samsung Biologics says its net profit fell 21.4% in Q4 2023 due largely to a one-off factor; The FDA denies approval for a newer formulation of tesamorelin that Theratechnologies proposed.
Five things for pharma marketers to know for Monday morning
Will Bernie Sanders subpoena Big Pharma execs?; Drugmakers raise the list prices for Ozempic and Mounjaro; Scientists identify a persistent change in a handful of blood proteins in people with long COVID.
Five things for pharma marketers to know on Tuesday morning
Novartis in talks to buy Cytokinetics; Boston Scientific acquires medtech company Axonics in $3.7 billion deal; Lilly’s Zepbound obesity drug reaches 25,000 new prescriptions mark.
Five things for pharma marketers to know on Tuesday
Medical complications rise at hospitals bought by PE firms; BMS snaps up radiation cancer therapy firm; Government ban on certain Apple Watches kicks in.